Non-Small-Cell Lung Cancer (NSCLC)-Drug Pipeline Analysis and Market Forecasts to 2015

May 11, 2010 - PRLog -- Summary
GlobalData, the industry analysis specialist's new report, "Non-Small Cell Lung Cancer (NSCLC)-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
GlobalData estimates the global NSCLC disease market to be $2.8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13.5% for the next seven years to reach $6.8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any drug that would offer better efficacy provided by the current players with increased safety than the current products.

GlobalData finds that that the emerging therapies in pipeline are expected to increase the competition. Emerging therapies have gained a positive perception among the physicians due to increased efficacy, safety and overall survival. The strong pipeline leads to the stiff competition in the NSCLC market and the existing market leaders need to be prepared to manage this expected dynamism in competition as there is a race to reach the blockbuster drug status.

Scope
The report analyzes market opportunities and challenges for the global NSCLC disease market. Its scope includes
-Annualized global NSCLC disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc.
-Analysis of the current and future market competition in the global NSCLC disease market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC disease.

Reasons to buy
The report will enhance your decision making capability. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global NSCLC disease market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC disease market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global NSCLC disease market landscape?-Identify, understand and capitalize.



Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 NSCLC: Market Characterization
2.1 Overview
2.1.1 Treatment Options for NSCLC
2.2 NSCLC Market Size
2.3 NSCLC Market Forecast and CAGR
2.4 Drivers and Barriers for NSCLC Market
2.4.1 Drivers for NSCLC Market
2.4.2 Barriers for NSCLC Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 NSCLC Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in NSCLC Market
3.3.1 Avastin (bevacizumab)
3.3.2 Taxotere (docetaxel)
3.3.3 Gemzar (gemcitabine)
3.3.4 Alimta (pemetrexed)
3.3.5 Tarceva (erlotinib)
3.3.6 Iressa (gefitinib)
3.4 Major Marketed Products Comparison in NSCLC Market
3.5 Key Takeaway
4 NSCLC Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 NSCLC Therapeutics-Promising Drugs Under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Nexavar (sorafenib)
4.4.2 Stimuvax
4.4.3 Sutent (sunitinib malate)
4.4.4 AMG 706 (motesanib)
4.4.5 Vargatef (BIBF 1120)
4.4.6 BIBW 2992 (Tovok)
4.4.7 Aflibercept ((VEGF Trap)
4.4.8 ASA404
4.4.9 Erbitux (cetuximab)
4.4.10 Figitumumab
4.5 NSCLC Therapeutics Market-Clinical Pipeline by Therapeutic Class
4.6 NSCLC Disease Pipeline-Pipeline by Clinical Phases of Development
4.6.1 NSCLC Therapeutics-Phase III Clinical Pipeline
4.6.2 NSCLC Therapeutics-Phase II Clinical Pipeline
4.6.3 NSCLC Therapeutics-Phase I Clinical Pipeline
4.6.4 NSCLC Therapeutics-Preclinical Pipeline
4.6.5 NSCLC Therapeutics-Drug Discovery Pipeline
4.7 Discontinued/Suspended Drugs for NSCLC
4.8 Key Takeaway
5 Global NSCLC: Implications for Future Market Competition
5.1 Strategic Competitor Assessment
6 Global NSCLC Market: Future Players in NSCLC Market
6.1 Introduction
6.2 F. Hoffmann-La Roche Ltd/Genentech, Inc.
6.2.1 Company Overview
6.2.2 Business Description
6.3 Pfizer Inc.
6.3.1 Company Overview
6.3.2 Business Description
6.4 Novartis AG
6.4.1 Company Overview
6.4.2 Business Description
6.5 Sanofi-aventis
6.5.1 Company Overview
6.5.2 Business Description
6.6 Boehringer Ingelheim GmbH
6.6.1 Company Overview
6.6.2 Business Description
6.7 Abraxis BioScience, Inc.
6.7.1 Company Overview
6.7.2 Business Description
7 Global NSCLC Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Tables
1.1 List of Tables
Table 1: NSCLC Treatment by Stage of the Disease, 2009
Table 2: Global NSCLC Therapeutics Market, Revenue Forecasts ($ m), 2000-2008
Table 3: Global NSCLC Therapeutics Market, Revenue Forecasts ($ m), 2009-2015
Table 4: Major marketed products comparison in Non-Small Cell Lung Cancer Market, 2009
Table 5: NSCLC Therapeutics-Most Promising Drugs Under Clinical Development, 2009
Table 6: NSCLC Therapeutics-Phase III Clinical Pipeline, 2009

...

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.